Abstract:Importance Cognitive impairment contributes significantly to clinical outcome and level of function in individuals with psychotic disorders. These impairments are present already at psychosis onset at a group level; however, the question of heterogeneity in cognitive function among patients has not been systematically investigated. Objective To provide an updated quantification of cognitive impairment at psychosis onset before patients receive potentially confounding antipsychotic treatment, and to investigate variability in cognitive function compared with healthy controls. Data Sources In this systematic review and meta-analysis, PubMed articles were searched up to September 15, 2022. Study Selection Original studies reporting data on cognitive function in antipsychotic drug–naive patients with first-episode psychosis (FEP) were included. Data Extraction and Synthesis Data were independently extracted by 2 researchers. Cognitive tasks were clustered according to 6 domains of the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery and the domain of executive function. Random-effects model meta-analyses of mean differences and coefficient of variation ratios (CVRs) were performed, as well as meta-regressions, assessment of study quality, and publication bias. Main Outcomes and Measures The main outcome measure was Hedges g for mean differences in cognition and CVR for within-group variability. Results Fifty studies were included in the analysis with a total of 2625 individuals with FEP (mean [SD] age, 25.2 [3.6] years, 60% male; 40% female) and 2917 healthy controls (mean [SD] age, 26.0 [4.6]; 55% male; 45% female). In all cognitive domains, the FEP group displayed significant impairment compared with controls (speed of processing: Hedges g = −1.16; 95% CI, −1.35 to −0.98; verbal learning: Hedges g = −1.08; 95% CI, −1.28 to −0.88; visual learning: Hedges g = −1.05; 95% CI, −1.27 to −0.82; working memory: Hedges g = −1.04; 95% CI, −1.35 to −0.73; attention: Hedges g = −1.03; 95% CI, −1.24 to −0.82; reasoning/problem solving: Hedges g = −0.90; 95% CI, −1.12 to −0.68; executive function: Hedges g = −0.88; 95% CI, −1.07 to −0.69). Individuals with FEP also exhibited a larger variability across all domains (CVR range, 1.34-1.92). Conclusions and Relevance Results of this systematic review and meta-analysis identified cognitive impairment in FEP before the initiation of antipsychotic treatment, with large effect sizes. The high variability within the FEP group suggests the need to identify those individuals with more severe cognitive problems who risk worse outcomes and could benefit the most from cognitive remediation.

Longitudinal changes in cognitive function in early psychosis: a meta-analysis with the MATRICS consensus cognitive battery (MCCB)

Free Long-Acting Injectables for Patients with Psychosis: A Step Forward.

Use of the Chinese version of the MATRICS Consensus Cognitive Battery to assess cognitive functioning in individuals with high risk for psychosis, first-episode schizophrenia and chronic schizophrenia: a systematic review and meta-analysis

The magnitude and variability of neurocognitive performance in first-episode psychosis: a systematic review and meta-analysis of longitudinal studies

Associations Between Age and Neurocognition in Individuals at Clinical High Risk and First-Episode Psychosis.

Meta-analysis of Cognitive Function in Chinese First-Episode Schizophrenia: MATRICS Consensus Cognitive Battery (MCCB) Profile of Impairment

Cognitive functions following initiation of antipsychotic medication in adolescents and adults at clinical high risk for psychosis: a naturalistic sub group analysis using the MATRICS consensus cognitive battery

Cognitive Impairments in First-Episode Drug-Naive and Chronic Medicated Schizophrenia: MATRICS Consensus Cognitive Battery in a Chinese Han Population.

Models of mild cognitive deficits in risk assessment in early psychosis

Neuropsychological Impairment in Prodromal, First-Episode, and Chronic Psychosis: Assessing Rbans Performance

The MATRICS Consensus Cognitive Battery (MCCB): Co-norming and Standardization in China.

SU40. Cognitive Function Deficits in High-Risk, First-Episode, and Chronic Schizophrenia

The MCCB impairment profile for schizophrenia outpatients: results from the MATRICS psychometric and standardization study

Cognitive Deficits in Subjects at Risk for Psychosis, First-Episode and Chronic Schizophrenia Patients.

A study of event-related potential P300 in subjects with clinical high risk of psychosis

Trajectories of Cognitive Function in First-Episode Psychosis: Associations to Clinical Outcomes and Biological Markers

Relationship between changes in metabolic syndrome constituent components over 12 months of treatment and cognitive performance in first-episode schizophrenia

Cognitive Function and Variability in Antipsychotic Drug–Naive Patients With First-Episode Psychosis

Eye Movement Characteristics for Predicting a Transition to Psychosis: Longitudinal Changes and Implications

Long-Term Changes in Cognition Among Patients With Schizophrenia Spectrum Disorders and Different Durations of Illness: A Meta-Analysis

Cognitive Dysfunction in a Psychotropic Medication-Naïve, Clinical High-Risk Sample from the ShangHai-At-Risk-for-Psychosis (SHARP) Study: Associations with Clinical Outcomes.